AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis

Introduction

GM1 gangliosidosis is a devastating, autosomal recessive lysosomal storage disorder caused by mutations in the GLB1 gene, which encodes the enzyme β-galactosidase. This deficiency leads to the toxic accumulation of GM1 ganglioside and its derivative, GA1, primarily within the central nervous system (CNS). Type II GM1 gangliosidosis, encompassing late-infantile and juvenile-onset forms, is characterized by progressive neurodegeneration, loss of motor skills, cognitive decline, and ultimately, premature death. Until recently, management was strictly palliative, as no disease-modifying therapies existed. However, the emergence of adeno-associated virus (AAV) vector technology has opened new frontiers in treating monogenic CNS disorders. A recent Phase 1-2 trial, published in the New England Journal of Medicine, investigates the safety and efficacy of an intravenous AAV9-based gene therapy designed to restore β-galactosidase activity.

Highlights

1. A single intravenous infusion of AAV9-GLB1 successfully increased β-galactosidase activity and decreased GM1 ganglioside concentrations in the cerebrospinal fluid (CSF) of all nine participants.
2. Clinical assessments indicated a stabilization of gross motor and expressive communication scores, contrasting with the progressive decline typically seen in historical controls.
3. Neuroimaging demonstrated reduced rates of cerebral atrophy and improved myelination patterns over a three-year follow-up period.
4. While the therapy was generally well-tolerated, all participants experienced transient elevations in liver enzymes, and one serious adverse event (vomiting) was attributed to the treatment.

Disease Burden and Unmet Medical Need

Type II GM1 gangliosidosis represents a significant clinical challenge. Patients typically meet early developmental milestones before experiencing a plateau and subsequent regression. The late-infantile form usually presents between 18 months and 3 years of age, while the juvenile form presents between 3 and 10 years. The pathophysiological hallmark is the progressive destruction of neurons and myelin due to substrate accumulation. Given the systemic and neurological nature of the disease, any effective therapy must cross the blood-brain barrier and achieve widespread enzymatic restoration. The lack of approved treatments has left families and clinicians with few options beyond supportive care for seizures, spasticity, and nutritional failure.

Study Design and Methodology

This phase 1-2, open-label, dose-escalation study (NCT03952637) enrolled nine children with type II GM1 gangliosidosis. Participants received a single intravenous infusion of AAV9 encoding human β-galactosidase. To mitigate potential immune responses against the viral vector or the newly expressed enzyme, a standardized immunosuppression regimen was administered.

The primary endpoint was safety, monitored through adverse event (AE) reporting, laboratory assessments, and physical examinations. Secondary endpoints were multifaceted, focusing on biochemical, clinical, and radiological markers. These included changes in CSF β-galactosidase activity and GM1 ganglioside levels, neurodevelopmental assessments (such as the Clinical Global Impression-Improvement [CGI-I] score), and longitudinal MRI scans to evaluate brain volume and myelination.

Key Findings: Safety and Tolerability

Over the three-year study period, a total of 124 adverse events were recorded. Among these, 30 were categorized by investigators as potentially related to the gene therapy. The most common related AEs included gastrointestinal disturbances (8 events) and laboratory abnormalities associated with inflammation (21 events). One participant experienced a serious adverse event of severe vomiting that required hospitalization, which was deemed treatment-related.

A notable finding was the elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in all nine participants. This transaminitis is a recognized phenomenon in systemic AAV gene therapy, likely reflecting an immune response to the viral capsid in the liver. Fortunately, these levels returned to baseline in all participants by the 18-month mark, following the protocol-defined immunosuppression and monitoring.

Biochemical and Neuroimaging Results

Biochemical data provided strong evidence of the therapy’s mechanistic success. All participants showed a measurable increase in CSF β-galactosidase activity. Commensurately, the concentration of the toxic substrate, CSF GM1 ganglioside, decreased. This biochemical shift suggests that the AAV9 vector successfully crossed the blood-brain barrier and transduced CNS cells, enabling the production and secretion of the functional enzyme.

Neuroimaging outcomes further supported these findings. MRI analysis revealed that the rate of cerebral atrophy was lower than what would be expected in the natural history of the disease. Furthermore, favorable changes in myelination were observed, suggesting that the restoration of enzymatic activity may facilitate some degree of neural repair or at least preserve existing white matter integrity.

Clinical Progression and Developmental Milestones

Clinically, the results were encouraging but nuanced. The median CGI-I score was 3 (minimal improvement) at two years and 4 (no change) at three years. While “no change” might seem modest, in the context of a rapidly progressive neurodegenerative disease, stabilization is a significant therapeutic achievement. Historical control data for GM1 gangliosidosis typically show a steady increase in CGI-I scores, reflecting continuous clinical worsening.

Specific developmental domains showed varying responses. Expressive communication and gross motor scores appeared to stabilize, which is a departure from the natural history of the disease. However, scores for fine motor skills and receptive communication continued to decrease in some participants. This divergence suggests that while gene therapy can alter the disease course, the timing of intervention and the specific neurological pathways involved may influence the degree of clinical rescue.

Expert Commentary

The results of this trial represent a landmark in the treatment of lysosomal storage diseases. The use of AAV9 to deliver a functional GLB1 gene intravenously addresses the critical need for a non-invasive yet CNS-penetrant delivery system. The stabilization of gross motor function and the biochemical evidence of substrate reduction are particularly compelling.

However, limitations must be acknowledged. The small sample size (n=9) and the open-label nature of the study mean that larger, controlled trials are necessary to confirm these findings. Additionally, the continued decline in fine motor skills suggests that intravenous delivery at the doses tested might not provide sufficient enzymatic coverage to all regions of the brain or that some damage present at baseline is irreversible. Future research may explore higher dosing, different delivery routes (such as intracisternal injection), or earlier intervention in the presymptomatic stage to maximize clinical benefit.

Summary and Conclusion

In conclusion, this Phase 1-2 trial demonstrates that AAV9-GLB1 gene therapy is a promising and generally safe intervention for Type II GM1 gangliosidosis. The therapy successfully achieves biochemical restoration within the CNS and slows the clinical and radiological progression of the disease. While liver enzyme elevations and gastrointestinal issues require careful management, the potential to transform a fatal pediatric condition into a manageable or stable one is a profound advancement in genetic medicine.

Funding and Trial Information

This study was funded by the National Human Genome Research Institute (NHGRI) and other supporting organizations. ClinicalTrials.gov number: NCT03952637.

References

1. Lewis CJ, et al. AAV9 Gene Therapy in Type II GM1 Gangliosidosis – A Phase 1-2 Trial. N Engl J Med. 2026. doi: 10.1056/NEJMoa2510935.
2. Tifft CJ, et al. The natural history of type II GM1 gangliosidosis. Genet Med. 2017;19(12):1370-1378.
3. Hinderer C, et al. Liver toxicity in AAV gene therapy: Mechanisms and mitigation strategies. Mol Genet Metab. 2021;133(1):51-58.